Sana Biotechnology (SANA)
NASDAQ:SANA
SANA Stock Chart & Stats
$3.15
$3.38(204.85%)
At close: 4:00 PM EST
$3.15
$3.38(204.85%)
Day’s Range― - ―
52-Week Range$1.32 - $6.55
Previous CloseN/A
Volume118.31M
Average Volume (3M)2.43M
Market Cap
$840.63M
Enterprise Value$863.63M
Total Cash (Recent Filing)$138.38M
Total Debt (Recent Filing)$78.86M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
May 13, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding266,866,880
10 Day Avg. Volume3,390,584
30 Day Avg. Volume2,429,628
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)6.41
Price to Sales (P/S)0.00
P/FCF Ratio-7.12
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-282.88
Enterprise Value/Ebitda-4.72
Forecast
1Y Price Target
$9.50Price Target Upside201.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.64
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durable Islet FunctionHIP-modified pancreatic islet cells maintained survival and insulin production without immunosuppression, supporting the immune‑evading platform's potential for sustained therapeutic effect.
In Vivo CAR‑T SG293 Commercial PotentialAn in vivo edited CAR‑T approach for SG293 achieved targeted delivery and deep B‑cell depletion in preclinical studies without conditioning, suggesting a one‑time, off‑the‑shelf treatment that could reduce manufacturing complexity and cost.
SC451 Regulatory And Manufacturing ReadinessEstablishment of a master cell bank for the stem cell‑derived SC451 program enables completion of toxicology studies and supports an investigational new drug application and early-stage clinical testing pathway.
Bears Say
C-peptide Interpretation UncertaintyMultiple non‑immune factors such as obesity, diet, and insulin resistance can affect C‑peptide measurements, creating uncertainty about whether observed changes reflect treatment effect or other health variables.
Financial Risk And Contingent LiabilitiesA substantial GAAP net loss combined with a finite cash runway and contingent success‑payment liabilities increases the risk of dilution from future financing needs.
Waning Graft FunctionMeasured C‑peptide levels decreased over time in the treated patient, indicating potential waning of graft function that could limit long-term clinical benefit.
Sana Biotechnology News
SANA FAQ
What was Sana Biotechnology’s price range in the past 12 months?
Sana Biotechnology lowest stock price was $1.32 and its highest was $6.55 in the past 12 months.
What is Sana Biotechnology’s market cap?
Sana Biotechnology’s market cap is $840.63M.
When is Sana Biotechnology’s upcoming earnings report date?
Sana Biotechnology’s upcoming earnings report date is May 13, 2026 which is in 34 days.
How were Sana Biotechnology’s earnings last quarter?
Sana Biotechnology released its earnings results on Mar 03, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.068.
Is Sana Biotechnology overvalued?
According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued.
Does Sana Biotechnology pay dividends?
Sana Biotechnology does not currently pay dividends.
What is Sana Biotechnology’s EPS estimate?
Sana Biotechnology’s EPS estimate is -0.16.
How many shares outstanding does Sana Biotechnology have?
Sana Biotechnology has 266,866,880 shares outstanding.
What happened to Sana Biotechnology’s price movement after its last earnings report?
Sana Biotechnology reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went down -2.799%.
Which hedge fund is a major shareholder of Sana Biotechnology?
Currently, no hedge funds are holding shares in SANA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sana Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.50 (201.59% Upside)
$9.50 (201.59% Upside)
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
37.61%
12-Months-Change
Fundamentals
Return on Equity
-141.99%
Trailing 12-Months
Asset Growth
-14.83%
Trailing 12-Months
Company Description
Sana Biotechnology
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
SANA Stock 12 Month Forecast
Average Price Target
$9.50
▲(201.59% Upside)
Technical Analysis
Geron
―
Editas Medicine
―
Crispr Therapeutics AG
―
Taysha Gene Therapies
―
Prime Medicine, Inc.
―
Ownership Overview
15.22% Insiders
12.69% Mutual Funds
16.66% Other Institutional Investors
46.53% Public Companies and Individual Investors